Pulmonary Arterial Hypertension – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Pulmonary Arterial Hypertension – Drugs In Development, 2023’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension
- The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Aadi Bioscience IncAbivax SA
Actelion Pharmaceuticals Ltd
Advantx Pharmaceuticals Inc
Advent Therapeutics Inc
Aeon Respire Inc
Aerami Therapeutics Inc
Aerovate Therapeutics Inc
Algorithm Sciences Inc
Alsymo
Alterras Therapeutics GmbH
Alveolus Bio Inc
Antlia Bioscience Inc
Apaxen
APEIRON Biologics AG
APT Therapeutics Inc
Aqualung Therapeutics Corp
Artin Bioscience Inc
AstraZeneca Plc
ATXA Therapeutics Ltd
Audax Therapeutics Ltd
Bayer AG
Biogen Inc
Biozeus Pharmaceutical SA
Boehringer Ingelheim International GmbH
Camurus AB
Capricor Therapeutics Inc
Celon Pharma SA
Cereno Scientific AB
Chengdu Dikang Pharmaceuticals Co Ltd
Chiesi Farmaceutici SpA
Claritas Pharmaceuticals Inc
Corsair Pharma Inc
Eli Lilly and Co
EspeRare Foundation
Everest Medicines Ltd
Excubio Pharmaceuticals Inc
Foresee Pharmaceuticals Co Ltd
Galectin Therapeutics Inc
GenThera Inc
GEXVal Inc
Gmax Biopharm LLC
GNI Group Ltd
Gossamer Bio Inc
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
Hunterian Medicine LLC
Imunon Inc
Insmed Inc
Interprotein Corp
Japan Tobacco Inc
Johnson & Johnson
KARE Biosciences Inc
Keros Therapeutics Inc
Lempo Therapeutics Ltd
Liquidia Corp
LTT Bio-Pharma Co Ltd
Mallinckrodt Plc
Merck & Co Inc
Mochida Pharmaceutical Co Ltd
Morphic Therapeutic Inc
Nadian Bio Ltd
Nippon Shinyaku Co Ltd
Nissan Chemical Corp
Northern Therapeutics Inc
Northwestern University
Novartis AG
OrphAI Therapeutics Inc
Osaka University
Pfizer Inc
Pharmosa Biopharm Inc
PulmoSIM Therapeutics
Q BioMed Inc
Radikal Therapeutics Inc
Recursion Pharmaceuticals Inc
Respira Therapeutics Inc
Resverlogix Corp
Reviva Pharmaceuticals Inc
Ribomic Inc
San Rocco Therapeutics LLC
Sanofi
Schrodinger Inc
Shanghai Aoquan Biomedical Technology Co Ltd
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Shiftbio Co Ltd
Structure Therapeutics Inc
Sulfateq BV
Systimmune Inc
Talem Therapeutics Inc
Tenax Therapeutics Inc
tiakis BIOTECH AG
Topadur Pharma AG
Triastek Inc
Tritech Biopharmaceuticals Co Ltd
United Therapeutics Corp
University of California San Diego
University of Cambridge
University of Pennsylvania
University of Strathclyde
Vascular BioSciences
Vasculonics LLC
VasoRx Inc
VasThera Co Ltd
Vicore Pharma AB
Vivus LLC
Voronoi Group
Wuxi Biocity Biopharma Co Ltd
Yale University
Zymedi